


Mondesi
09/908955

```
=> d 13 que stat;fil hcaplus;s 13  
L1                      STR
```



VAR G1=O/NH

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L3 155 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 209 ITERATIONS

155 ANSWERS

SEARCH TIME: 00.00.01

COST IN U. S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

162.62

162.83

FILE 'HCAPLUS' ENTERED AT 10:35:03 ON 09 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

PLEASE SEE REEL 00000000 FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Mar 2005 VOL 142 ISS 11
FILE LAST UPDATED: 8 Mar 2005 (20050308/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


L4

3 L3

=> d 1-3 cbib abs hitstr

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 2003:912843 Document No. 139:381756 Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus. Sakeena, Anil K.; Girijavallabhan, Viyyoor Moopan; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Cuong; Zhu, Zhaoning; Njoroge, P. George; Arasappan, Aadhok; Parekh, Tejal; Ganguly, Asit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick J.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerite; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua (USA). U.S. Pat. Appl. Publ. US 2003216325 A1 20031120, 629 pp. (English). CODEN: USXXCO. APPLICATION: US 2001-908955 20010719.


GI



AB The invention discloses novel peptides I (Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkyloxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with proviso) which have HCV protease inhibitory activity as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders associated with the HCV protease.

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Glycinamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394729-04-5 HCAPLUS
 CN Glycinamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Thus, peptide II was prep'd. by the solid-phase method and showed Ki = 1-100 nM (category A) in the HCV continuous assay.


IT 394729-48-3P 394729-98-4P 394729-10-5P
 394729-13-6P 394729-16-9P 394729-18-1P
 394729-22-3P 394729-23-8P
 394729-38-7P 394729-31-8P 394729-32-9P
 394729-33-0P 394729-34-1P 394729-40-9P
 394729-44-3P 394729-45-4P 394729-46-5P
 394729-47-6P 394729-50-5P 394729-51-2P
 394729-52-3P 394729-58-9P 394729-65-8P
 394729-67-0P 394729-82-9P 394729-93-0P
 394729-07-4P 394729-89-6P 394730-38-2P
 394730-39-3P 394730-40-6P 394730-43-7P
 394730-42-8P 394730-45-1P 394730-46-2P
 394730-48-4P 394730-49-5P 394730-53-1P
 394730-54-2P 394730-55-3P 394730-61-1P
 394730-62-3P 394730-63-3P 394730-66-6P
 395646-10-0P 395645-14-4P 395645-08-2P
 395646-26-1P 395647-37-7P 395647-42-4P
 395647-44-6P 395647-45-7P 395647-46-8P
 395647-59-5P 395647-71-9P 395647-75-3P
 395648-09-6P 395648-50-7P 395648-57-4P
 395648-58-5P 395648-60-9P 395648-63-2P
 395650-31-4P 395650-32-5P 395650-47-2P
 395650-49-4P 395650-51-0P 395650-85-2P

RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394724-48-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-((2S)-cyclohexyl-1-(cyclohexylamino)carbonyl)amino)acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394728-98-4 HCAPLUS

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B


RN 394729-13-6 HCAPLUS
 CN β -Alaninamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-16-9 HCAPLUS
 CN Glycinamide, (2S)-2-(cyclohexyl-1-(1,1-dimethylethoxy)carbonyl)glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-18-1 HCPLUS
 CN Glycaminamide, 3-methyl-N-[(phenylamino)carbonyl]-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-19-2 HCPLUS
 CN β -Alanine, N-[(1,1-dimethylethyl)amino]carbonyl-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-22-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-butenylamino)oxoacetyl]-4-pentenyl-6,6-dichloro-3-[(2S)-3,3-dimethyl-1-oxo-2-[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]butyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-23-8 HCPLUS
 CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-[(2-[(1,1-dimethylethyl)sulfonyl]ethyl)amino]oxoacetyl)-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-30-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino]carbonyl]amino)cyclohexylacetyl]-6,6-dichloro-N-[(oxo-2-propenylamino)acetyl]-4-pentenyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-31-8 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl-N-[(3-(1-methylcyclopentyl)-3-oxopropyl)amino]oxoacetyl]-4-pentenyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-32-9 HCPLUS
 CN β -Alanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl]-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-33-0 HCPLUS
 CN β -Alanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl]-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-, 1-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394729-34-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[(2S)-cyclohexyl[(1-(1-dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-[(4-methyl-3-oxopentyl)amino]oxoacetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-40-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-[(3-butenylamino)oxoacetyl]-4-pentenyl]-6,6-dichloro-3-[(2S)-2-[(1-(1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-44-3 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-45-4 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-46-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[(2S)-cyclohexyl[(1-(1-dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-[(2-propenylamino)acetyl]-4-pentenyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-47-6 HCPLUS
 CN β -Alaninamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-50-1 HCPLUS
 CN Glycaminamide, N-[(1-(1-dimethylethyl)amino)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-51-2 HCPLUS
 CN β -Alanine, N-[(1S,4R)-bicyclo[2.2.1]hept-2-ylamino]carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-52-3 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo-2-propenylamino)acetyl]-4-pentenyl]amino]carbonyl-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-58-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-2-[(1S,4R)-bicyclo[2.2.1]hept-2-ylamino]carbonyl]amino]cyclohexylacetyl]-N-[(1-(3-butenylamino)oxoacetyl)-4-pentenyl]-6,6-dichloro-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-65-8 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-(methylamino)oxoacetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-67-0 HCPLUS
 CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo-2-propenyl)acetyl]-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-82-9 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-83-0 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394729-87-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-cyclohexyl-2-[(1,1-dimethylethyl)amino]carbonyl]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394729-89-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]-3,3-dimethyl-1-oxobutyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-38-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-


2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl[(cyclohexylamino)carbonyl]amino]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394730-39-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-(aminooxocetyl)butyl]-6,6-dichloro-3-[(2S)-cyclohexyl[[{(1,1-dimethylethyl)amino}carbonyl]amino]acet-yl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-42-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394730-45-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-


Searched by: Mary Hale 571-272-2507 REM 1D86



RN 394730-40-6 HCAPLUS

CN Carbamic acid, (1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-41-7 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl[[{(1,1-dimethylethyl)amino}carbonyl]amino]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 394730-46-2 HCAPLUS

CN Carbamic acid, (1S)-2-[(1S,2S,5R)-2-[(1-(aminooxocetyl)butyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-48-4 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-49-5 HCAPLUS

CN Carbamic acid, ((1S)-2-[(1S,2S,5R)-2-[(1-amino-2-oxoethyl)butyl]amino]carbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl)-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-53-1 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1-(amino-2-oxoethyl)butyl)-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-54-2 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1-(amino-2-oxoethyl)butyl)-6,6-dichloro-3-[(2S)-2-(2,3-dihydro-1H-inden-2-yl)][(1,1-dimethylethyl)amino]carbonyl]amino]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-55-3 HCAPLUS

CN Carbamic acid, ((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl)carbonyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-61-1 HCAPLUS

CN Carbamic acid, ((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl)carbonyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-62-2 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-cyclohexyl][[(1,1-dimethylethyl)amino]carbonyl]amino]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 394730-63-3 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-cyclohexyl][[(1,1-dimethylethyl)amino]carbonyl]amino]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-66-6 HCAPLUS


CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-(2,3-dihydro-1H-inden-2-yl)][(1,1-dimethylethyl)amino]carbonyl]amino]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395645-10-0 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395645-14-4 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(1-(amino)oxoacetyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395645-88-2 HCPLUS
 CN Carbamic acid, [2-((2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395646-26-1 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-37-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl-1-((cyclohexylamino)carbonyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-42-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl-1-((1,1-dimethylethyl)amino)carbonyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-44-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl-1-((1,1-dimethylethyl)amino)carbonyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395647-45-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl-1-((1,2,2-trimethylpropyl)amino)carbonyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395647-46-8 HCPLUS

CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, tricyclo[3.3.1.13,7]dec-1-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395647-69-5 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-(aminooxoacetyl)butyl]-6,6-dichloro-3-[(2S)-cyclohexyl[[(1,1-dimethylethyl)amino]carbonyl]amino]acetyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-71-9 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-

2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-[(cyclohexylamino)carbonyl]amino] (2,3-dihydro-1H-inden-2-yl)acetyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-75-3 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-

2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-(2,3-dihydro-1H-inden-2-yl)[[(1,1-dimethylethyl)amino]carbonyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395648-09-6 HCPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 395648-50-7 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-

2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]-3,3-dimethyl-1-oxobutyl-, (2S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-54-8 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-

2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395648-58-5 HCPLUS


CN Carbamic acid, [(1S)-1-[(2S)-2-[(1-(aminooxoacetyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-60-9 HCPLUS
 CN Carbamic acid, [(1S)-1-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-63-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
 N-(3-amino-1-(cyclopropylmethyl)-
 2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino)-3,3-dimethyl-1-oxobutyl-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395650-47-2 HCPLUS
 CN Glycinamide, 2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl- (2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxacyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



RN 395650-49-4 HCPLUS

Searched by: Mary Hale 571-272-2507 REM 1D86


Absolute stereochemistry.



RN 395650-31-4 HCPLUS

CN Glycinamide,
 (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl- (2S)-
 6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-
 oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395650-32-5 HCPLUS

CN Glycinamide,
 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl- (2S)-6,6-
 dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoylglycyl-
 N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

CN Glycinamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl- (2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395650-51-8 HCPLUS

CN Glycinamide,
 (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl- (2S)-
 6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-
 oxacyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-85-2 HCPLUS

CN Carbamic acid,
 [(1S)-1-cyclohexyl-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo(2-

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 propenylamino)acetyl]butyl]amino[carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 2-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 2003:591204 Document No. 139:14928 Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus. Sakeena, Anil K.; Girijavallabhan, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank;

McCormick, Jiping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane

L.; Chan, Tin-yeu; Liu, Yi-tsung; Zhu, Zhaoning; Nyjoroge, George F.;

Araseppan, Ashok; Parekh, Tejal; Ganguly, Ashish K.; Chen, Kevin X.;

Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerite;


Tamura, Susan Y.; Wu, Wanli; Hendriata, Siske; Huang, Yuhua; Wong, Jessie K.; Nair, Latha G. (Schering Corporation, USA; Corvus International, Inc.);

Dendreon Corp.). PCT Int. Appl. WO 2003062265 A2 20030731, 633 pp.

DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,

BZ, CA, CH, CN, CO, CR, CZ, DE, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXDD2. APPLICATION: WO 2003-US1430 20030116. PRIORITY: US 2002-52386 20020118.

GI



AB The invention discloses novel peptides I (Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkoxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy,

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 alkylamino, arylamino, alkylarylamino, arylamino, heteroaryl amino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, NH, CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is a bond; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos) which have HCV protease inhibitory activity as well as methods for prep. such compds. In another embodiment, the invention discloses pharmaceutical compnds. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus, peptide II was prep'd. and showed Ki = 1-100 nM (category A) in the HCV continuous assay.

IT 394724-48-2P 394727-53-8P 394727-69-6P
 394727-70-9P 394727-71-0P 394727-73-2P
 394727-96-3P 394727-97-0P 394728-02-0P
 394728-03-1P 394728-05-3P 394728-09-7P
 394728-20-2P 394728-28-0P 394730-61-1P
 394730-62-2P 395645-10-0P 395645-14-4P
 395645-88-2P 395646-26-1P 395647-37-7P
 395647-42-4P 395647-44-6P 395647-45-7P
 395647-46-8P 395647-69-5P 395647-71-9P
 395647-75-3P 395648-09-6P 395648-50-7P
 395648-57-4P 395648-58-5P 395648-60-9P
 395648-63-2P 395650-31-4P 395650-32-5P
 395650-47-2P 395650-49-4P 395650-51-8P
 395657-22-4P 395659-36-6P 395660-23-8P
 395660-24-9P 395660-25-0P 395660-29-4P
 395660-32-9P 395660-38-5P 395660-54-5P
 395660-64-7P 395660-71-6P 395660-72-7P
 395675-25-8P 395675-26-9P 395675-30-3P
 395675-58-7P 395675-76-9P 395675-83-8P
 395675-84-9P 395675-85-0P 395675-89-4P
 395675-90-7P 395675-92-9P 395676-09-1P
 395676-11-5P 395676-12-6P 395676-14-8P
 395676-16-0P 395676-17-1P 395676-25-1P
 395676-31-9P 395676-41-1P 395676-43-3P
 395676-40-0P 395676-49-9P 395676-59-1P
 395676-60-4P 395676-67-1P 395676-77-3P
 395676-70-4P 395676-83-1P 395676-88-6P
 395676-93-3P 395676-94-4P 395676-98-8P
 395676-99-9P 395677-01-6P 395677-02-7P
 395677-14-1P 395677-15-2P 395677-18-5P
 395677-19-6P 395677-20-9P 395677-26-5P
 395677-27-6P 395677-31-2P 395677-32-3P
 395677-35-6P 395677-36-7P 395677-37-8P
 395677-46-9P 395677-47-0P 395677-56-1P
 395677-58-3P 395677-59-4P 395677-60-7P
 395677-80-1P 395677-01-2P 395678-43-9P
 395678-50-8P 395678-51-9P 395678-52-0P

RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


Searched by: Mary Hale 571-272-2507 REM 1D86

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (prepn. of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394724-48-2 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl((cyclohexylamino)carbonyl)amino]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394727-53-8 HCAPLUS

CN Carbamic acid, (2-[(1S,2S,5R)-6,6-dichloro-2-[(1-[oxo(2-propenylamino)acetyl]-4-pentenyl]aminocarbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 394727-69-6 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-[(3-butenylamino)oxoacetyl]-


L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 4-pentenyl]-6,6-dichloro-3-[2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl] - (9CI) (CA INDEX NAME)



RN 394727-70-9 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide.
 N-[1-[(3-butenylamino)oxoacetyl]-4-pentenyl]-6,6-dichloro-3-[2-[(cyclohexylamino)carbonyl]amino]-3,3-dimethyl-1-oxobutyl] - (9CI) (CA INDEX NAME)




RN 394727-71-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide.
 N-[1-[(3-butenylamino)oxoacetyl]-4-pentenyl]-6,6-dichloro-3-[3,3-dimethyl-1-oxo-2-[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]butyl] - (9CI) (CA INDEX NAME)




RN 394727-73-2 HCAPLUS
 CN Carbamic acid, [2-[2-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 cyclohexyl-2-oxoethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 394727-96-9 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide.
 6,6-dichloro-3-[cyclohexyl-[(1,1-dimethylethyl)amino]carbonyl]acetyl]-N-[1-[oxo(2-propenylamino)acetyl]-4-pentenyl] - (9CI) (CA INDEX NAME)




RN 394727-97-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino)cyclohexylacetyl]-6,6-dichloro-N-[1-[oxo(2-propenylamino)acetyl]-4-pentenyl] - (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 394728-02-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[cyclohexyl-[(1,1,3,3-tetramethylbutyl)amino]carbonyl]amino]acetyl]-N-[1-[oxo(2-propenylamino)acetyl]-4-pentenyl] - (9CI) (CA INDEX NAME)




RN 394728-03-1 HCAPLUS
 CN Glycaminide,
 N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoyl-N-(phenylmethyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 394728-05-3 HCAPLUS
 CN β -Alaninamide, 2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl) - (9CI) (CA INDEX NAME)




RN 394728-09-7 HCAPLUS
 CN β -Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]valyl-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl) - (9CI) (CA INDEX NAME)




RN 394728-20-2 HCPLUS
 CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl)-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394728-28-0 HCPLUS
 CN Glycaminide, N-[(1,1-dimethylethyl)amino]carbonyl]-3-methylvalyl-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 394730-61-1 HCPLUS
 CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-62-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-cyclohexyl-[(1,2,2-trimethylpropyl)amino]carbonyl]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395645-10-0 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395645-14-4 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(1-(aminooxoacetyl)butyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395645-88-2 HCPLUS
 CN Carbamic acid, [2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395646-26-1 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-37-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl|[(cyclohexylamino)carbonyl]aminolacetyl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-42-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl|{[(1,1-dimethylethyl)amino]carbonyl}amino]acetyl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-44-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl|{[(1,1-dimethylethyl)amino]carbonyl}acetyl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-45-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl|{[(1,2,2-trimethylpropyl)amino]carbonyl}amino]acetyl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-46-8 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropylamino)carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, tricyclo[3.3.1.13,7]dec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-69-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-(aminooxoacetyl)butyl]-6,6-dichloro-3-[(2S)-cyclohexyl|{[(1,1-dimethylethyl)amino]carbonyl}amino]acet-yl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-71-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-{[(cyclohexylamino)carbonyl]amino}-(2,3-dihydro-1H-inden-2-yl)acetyl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-75-3 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-{[(2,3-dihydro-1H-inden-2-yl)amino]carbonyl}amino]acetyl]-. (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-09-6 HCAPLUS
 CN Carbamic acid, [(1S)-1-[(2S)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-50-7 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-60-9 HCAPLUS
 CN Carbamic acid, [(1S)-1-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395648-63-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)

Searched by: Mary Hale 571-272-2507 REM 1D86



RN 395648-57-4 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclohexylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395648-58-5 HCAPLUS
 CN Carbamic acid, [(1S)-1-[(2S)-2-[(1-aminooxoacetyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 395650-31-4 HCAPLUS
 CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395650-32-5 HCAPLUS
 CN Glycinamide, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)




RN 395660-29-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(1bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino)cyclohexylacetyl]-N-1-[(3-butenylamino)oxoacetyl]-4-pentenyl]-6,6-dichloro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-32-9 HCPLUS
 CN Carbamic acid, [2-((2S)-2-[(1-((3-butenylamino)oxoacetyl)-4-pentenyl)amino]carbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-38-5 HCPLUS
 CN β -Alaninamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-54-5 HCPLUS
 CN Carbamic acid, [1-cyclohexyl-2-((2S)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl)butyl]amino]carbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-64-7 HCPLUS
 CN Glycaminamide, [2-(2-(2-dihydro-1H-inden-2-yl)-N-((1,1-dimethylethoxy)carbonyl)glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxohexanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-71-6 HCPLUS
 CN β -Alanine, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-72-7 HCPLUS
 CN β -Alanine, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569675-25-8 HCPLUS
 CN Carbamic acid, [1-cyclohexyl-2-((1S,2S,5R)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl)butyl]amino]carbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl-, (1S,2S)-2-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569675-26-9 HCAPLUS
 CN Carbamic acid,
 [(1S)-1-[(1S,2S,5R)-6,6-dichloro-2-[(1-(cyclobutylmethyl)-
 2,3-dioxo-3-(2-propenylamino)propyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-
 3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 569675-38-3 HCAPLUS
 CN Carbamic acid,
 [(1S)-2-[(1S,2S,5R)-2-[(1-(aminooxoacetyl)butyl]amino]carbonyl]-
 6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-
 (2S)-2-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569675-58-7 HCAPLUS
 CN Carbamic acid,
 [(1S)-1-[(1S,2S,5R)-6,6-dichloro-2-[(1-(cyclobutylmethyl)-2,3-
 dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-
 yl]carbonyl]-2,2-dimethylpropyl-, (1S,2R,4R)-bicyclo[2.2.1]hept-2-yl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569675-76-9 HCAPLUS
 CN Carbamic acid,
 [(1S)-1-[(1S,2S,5R)-6,6-dichloro-2-[(1-(cyclobutylmethyl)-
 3-(cyclopropylamino)-2,3-dioxopropyl]amino]carbonyl]-3-
 azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569675-83-8 HCAPLUS
 CN Carbamic acid,
 [(1S)-1-[(1S,2S,5R)-6,6-dichloro-2-[(1-(cyclobutylmethyl)-
 3-(methoxyamino)-2,3-dioxopropyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-
 yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.





RN 569675-84-9 HCAPLUS
 CN Glycaminide,
 N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-
 6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -
 oxocyclobutanebutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569675-85-0 HCAPLUS
 CN Glycaminide,
 N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-
 6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -
 oxocyclobutanebutanoyl-N-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 569675-89-4 HCPLUS
CN Glycaminamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl]glycyl-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanoyl-N-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569675-90-7 HCPLUS
CN Glycaminamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-11-5 HCPLUS
CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(1-amino-oxoacetyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 2,2,2-trifluoro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-12-6 HCPLUS
CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2,2-trifluoro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569675-92-9 HCPLUS
CN Glycaminamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-09-1 HCPLUS
CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 2,2,2-trifluoro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-14-8 HCPLUS
CN Glycaminamide, N-[(1,1-dimethylethyl)amino]carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-16-0 HCPLUS
CN Glycaminamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-17-1 HCAPLUS
 CN Carboxylic acid, [(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-25-1 HCAPLUS
 CN Glycaminamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-31-9 HCAPLUS
 CN Glycaminamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonylglycyl-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-41-1 HCAPLUS
 CN Glycaminamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonylglycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569676-43-3 HCAPLUS
 CN Glycaminamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonylglycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoyl-, 1-methyl-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569676-48-8 HCAPLUS
 CN Glycaminamide, N-[(1,1-dimethylethyl)amino]carbonyl-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 569676-49-9 HCAPLUS
 CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2,2-trifluoro-1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 569676-59-1 HCAPLUS

CN Glycine, N-[(1,1-dimethylethylamino)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclopropanebutanoyl-, 1-methyl-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569676-60-4 HCAPLUS

CN Glycine, N-[(1,1-dimethylethylamino)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanebutanoyl-, 1-methyl-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 569676-67-1 HCAPLUS



RN 569676-67-1 HCAPLUS

CN β -Alanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethylamino)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclobutanebutanoyl-, 1-methyl-1-phenylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 569676-77-3 HCAPLUS

CN Glycynamide, 3-methyl-N-[(2,2,2-trifluoro-1,1-dimethylethoxy)carbonyl]-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 569676-78-4 HCAPLUS

CN Glycynamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethylamino)carbonyl]glycyl-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl- β -amino- α -oxocyclopropanebutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 569676-83-1 HCAPLUS
CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 569676-88-6 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexene-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-(2,3-dihydro-1H-inden-2-yl)][[(1,1-dimethylethyl)amino]carbonyl]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 569676-93-3 HCAPLUS
CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl-, 1-cyano-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569676-94-4 HCPLUS
 CN Carbamic acid, ((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl)carbonyl-2,2-dimethylpropyl-, 1-cyano-1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569676-98-8 HCPLUS
 CN Propanoic acid, 2-[(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]amino]carbonyl]oxy]-2-methyl-, methyl ester (9CI)

L4 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl)carbonyl-2,2-dimethylpropyl-, 1-cyano-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569677-02-7 HCPLUS
 CN Propanoic acid, 2-[(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl]amino]carbonyl]oxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





Absolute stereochemistry.



RN 569676-99-9 HCPLUS
 CN Propanoic acid, 2-[(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl]amino]carbonyl]oxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 569677-01-6 HCPLUS
 CN Carbamic acid, ((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]oxy)-2-methyl-

L4 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl)carbonyl-2,2-dimethylpropyl-, 1-cyano-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569677-14-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-2-[(2-(acetyloxy)methyl)-1-methylethyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxabutyl]-N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-, (1S,2S,5R)- (9CI) (CA INDEX NAME)




RN 569677-15-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-2-[(2-(acetyloxy)-1,1-dimethylethyl]amino]carbonyl]amino]cyclohexylacetyl]-N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569677-15-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-2-[(2-(acetyloxy)-1,1-dimethylethyl]amino]carbonyl]amino]cyclohexylacetyl]-N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569677-18-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-2-[(2-(acetoxy)-1,1-dimethylethyl)amino]carbonyl]amino-3,3-dimethyl-1-oxobutyl-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569677-19-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]carbonyl]amino-3,3-dimethyl-1-oxobutyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]carbonyl]amino-3,3-dimethyl-1-oxobutyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569677-27-6 HCPLUS
 CN Alanine, N-[(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropylamino]carbonyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569677-31-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-3,3-dimethyl-1-oxo-2-[(1,2,2-



RN 569677-20-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl-[(2-hydroxy-1,1-dimethylethyl)amino]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 569677-26-5 HCPLUS
 CN Alanine, N-[(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-


L4 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]butyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569677-32-3 HCPLUS
 CN Cyclopentanecarboxylic acid, 1-[(1S)-2-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]amino]carbonyl]-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569677-35-6 HCPLUS


L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Cyclopentanecarboxylic acid, 1-[[((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]amino-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569677-36-7 HCAPLUS
 CN Cyclopentanecarboxylic acid, 1-[[((1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]amino-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569677-37-8 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-2-[(1-(acetoxy)methyl)-2,2-dimethylpropyl]amino]carbonyl]amino]-3,3-dimethyl-

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 569677-56-1 HCAPLUS
 CN L-Valine, N-[(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Searched by: Mary Hale 571-272-2507 REM 1D86


L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 1-oxobutyl]-N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]amino-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569677-46-9 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(1-(acetoxy)methyl)-2,2-dimethylpropyl]amino]carbonyl]amino)cyclohexylacetyl]-N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]amino-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569677-47-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-[(1-(hydroxymethyl)-2,2-dimethylpropyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 569677-58-3 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-cyclohexyl-[(1R)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino]carbonyl]amino]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 569677-59-4 HCAPLUS
 CN Carboxamic acid, [(1S)-1-[(1S,2S,5R)-2-[(1R)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 569677-60-7 HCAPLUS

CN Carbamic acid,
(1S)-1-[(1S)-3-amino-1-(cyclobutylmethyl)-
2,3-dioxopropyl]amino[carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-
yl[carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 569677-80-1 HCAPLUS


CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
N-(3-amino-1-(cyclopropylmethyl)-
2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-[(1S)-1-(methoxymethyl)-2,2-trimethylbicyclo[2.2.1]hept-2-yl ester (9CI) (CA INDEX NAME)RN 569678-50-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
N-(3-amino-1-(cyclopropylmethyl)-
2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-3,3-dimethyl-1-oxo-2-
[(tricyclo[3.3.1.13.7]dec-1-ylamino)carbonyl]amino]butyl-, (1S,2S,5R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 569678-51-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-
2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-3,3-dimethyl-1-oxo-2-
[(tricyclo[3.3.1.13.7]dec-1-ylamino)carbonyl]amino]butyl-, (1S,2S,5R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 569677-81-2 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-
2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1S)-1-(methoxymethyl)-2,2-
dimethylpropyl]amino[carbonyl]amino)-3,3-dimethyl-1-oxobutyl]-,
(1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 569678-43-9 HCAPLUS

CN Carbamic acid,
(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-
2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-
yl[carbonyl]-2,2-dimethylpropyl-, (1R,2R,4S)-1,3,3-
trimethylbicyclo[2.2.1]hept-2-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 569678-52-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-
2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl-[(tricyclo[3.3.1.13.7]dec-
1-ylamino)carbonyl]amino]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 569682-38-8 HCAPLUS
CN Glycinamide,
(2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl)glycyl-
1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-
β-amino-α-oxocyclobutanebutanoyl-N-(phenylmethyl)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 2002:90062 Document No. 136:167698 Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus. Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Lovey, Raymond G.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu, Zhaoming; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siske; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerite; Tamura, Susan Y. (Schering Corporation, USA; Corvas International, Inc.). PCT Int. Appl. WO 200208244 A2 20020131. S36 pp. DESIGNATED STATES: W: AE, AG, AL, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA; RW: AT, BE, BP, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXDXD2. APPLICATION: WO 2001-US22678 20010719. PRIORITY: US 2000-PIV20108 20000721.

AM,

AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA; RW: AT, BE, BP, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXDXD2. APPLICATION: WO 2001-US22678 20010719. PRIORITY: US 2000-PIV20108 20000721.

GI



AB Peptides I were prepared wherein Y is alkyl, alkyl-aryl, heteroaryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkylheteroaryl, cycloalkyl, alkoxy, alkylalkoxy, aryloxy, heteroaryloxy, heterocycloalkoxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino and heterocycloalkylamino; R1 is acyl, borate; Z is selected from O, N, CH or CR; W, Q, G, J, L, M independently maybe present or absent; W is C=O, C=S, C≡N-CN, or SO; Q is CH, N, P, alkylidene, O, amine, S, or SO; A is O, CH, alkylidene, amine, S, SO or bond; E is CH, N, alkylidene, or double bond; G is alkylidene; J is alkylidene, SO, NH, NR, O; L is CH, alkylidene, O, S or NR; M is O, NR, S, SO, alkylidene; p is 0 to 6; and R-R5 are independently selected from the group consisting of H: alkyl; alkenyl; cycloalkyl; heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halogen, (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, which have HCV protease inhibitory activity as well as methods for prep. such compds. In another embodiment, the invention discloses pharmaceutical compds. comprising such

compds. as well as methods of using them to treat disorders assoc. with the HCV protease. Thus peptide II was prep. and tested as antiviral agent and NS3-serine protease inhibitor of hepatitis C virus with K_i ranges in category A = 1-100 nM; category B = 101-1,000 nM; category C > 1000 nM. Also disclosed is the use of I for the manuf. of a medicament for the treatment of HCV, AIDS and related disorders.


IT 394724-48-29 394727-58-89 394727-69-69
 394727-70-99 394727-71-09 394727-73-29
 394727-96-99 394727-97-09 394728-02-09
 394728-03-19 394728-05-39 394728-09-79
 394728-20-29 394728-28-09 394728-98-49
 394729-04-59 394729-13-69 394729-16-99
 394729-18-19 394729-19-29 394729-22-79
 394729-23-89 394729-30-79 394729-31-89
 394729-32-99 394729-33-09 394729-34-19
 394729-40-99 394729-44-39 394729-45-49
 394729-46-59 394729-47-69 394729-50-19
 394729-51-29 394729-52-39 394729-58-99
 394729-65-09 394729-67-09 394729-82-99
 394729-83-09 394729-87-49 394729-89-69
 394730-18-29 394730-39-39 394730-40-69
 394730-41-79 394730-42-89 394730-45-19
 394730-46-29 394730-48-49 394730-49-59
 394730-53-19 394730-54-29 394730-55-39
 394730-61-19 394730-62-29 394730-63-39
 394730-66-69 395645-10-09 395645-34-49
 395645-88-29 395645-26-19 395647-37-79
 395647-14-49 395647-44-69 395647-45-79
 395647-46-09 395647-69-59 395647-71-99
 395647-75-39 395648-09-69 395648-50-79
 395648-57-49 395648-58-59 395648-60-99
 395649-63-29 395650-34-49 395650-32-59
 395650-77-29 395650-49-49 395650-51-89
 395657-22-49 395659-36-69 395660-23-89
 395660-24-99 395660-25-09 395660-29-49
 395660-32-99 395660-38-59 395660-54-59
 395660-64-79 395660-71-69 395660-72-79
 395660-85-29

RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
 (preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394724-48-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl][(cyclohexylamino)carbonyl]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 394727-53-8 HCAPLUS
 CN Carbamic acid, [2-((1S,2S,5R)-6,6-dichloro-2-[(1-oxo-2-propenylamino)acetyl]-4-pentenyl)amino]carbonyl-3-azabicyclo[3.1.0]hex-3-yl-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 394727-69-6 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-((3-butenylamino)oxoacetyl)-4-pentenyl]-6,6-dichloro-3-[(1,1-dimethylethylamino)carbonyl]amino]-3,3-dimethyl-1-oxobutyl- (9CI) (CA INDEX NAME)



RN 394727-70-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
 N-[1-[(3-butenylamino)oxoacetyl]-
 4-pentenyl]-6,6-dichloro-3-[2-[(cyclohexylamino)carbonyl]amino]-3,3-
 dimethyl-1-oxobutyl] - (9CI) (CA INDEX NAME)




RN 394727-71-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
 N-[1-[(3-butenylamino)oxoacetyl]-
 4-pentenyl]-6,6-dichloro-3-[3,3-dimethyl-1-oxo-2-
 [(tricyclo[3.3.1.13.7]dec-1-ylamino)carbonyl]amino]butyl] - (9CI) (CA
 INDEX NAME)




RN 394727-73-2 HCPLUS
 CN Carbamic acid, [2-[2-[(1-[(3-butenylamino)oxoacetyl]-4-
 pentenyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-
 cyclohexyl-2-oxoethyl] -, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 394728-02-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-
 [(cyclohexyl)[(1,1,3,3-tetramethylbutyl)amino]carbonyl]amino]acetyl] -N-[1-
 (oxo(2-propenylamino)acetyl]-4-pentenyl] - (9CI) (CA INDEX NAME)




RN 394728-03-1 HCPLUS
 CN Glycinamide, N-[(1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-
 6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoyl-N-
 (phenylmethyl) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 394728-05-3 HCPLUS
 CN β -Alaninamide, 2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-
 dimethylethoxy)carbonyl]glycyl-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-
 carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl) - (9CI) (CA
 INDEX NAME)




RN 394727-96-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
 6,6-dichloro-3-[(cyclohexyl)[(1,1-
 dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-(oxo(2-
 propenylamino)acetyl]-4-pentenyl] - (9CI) (CA INDEX NAME)



RN 394727-97-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(bicyclo[2.2.1]hept-2-
 ylaminocarbonyl)amino]cyclohexylacetyl]-6,6-dichloro-N-[1-(oxo(2-
 propenylamino)acetyl]-4-pentenyl] - (9CI) (CA INDEX NAME)





RN 394728-09-7 HCPLUS
 CN β -Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]valyl-6,6-dichloro-3-
 azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-
 dimethylethyl) - (9CI) (CA INDEX NAME)




RN 394728-20-2 HCPLUS
 CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-6,6-dichloro-2-[(1-
 oxo(2-propenylamino)acetyl]-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-
 yl]carbonyl-2,2-dimethylpropyl] -, 1,1-dimethylethyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 394728-28-0 HCPLUS
 CN Glycinamide, N-[(1,1-dimethylethyl)amino]carbonyl]-3-methylvalyl-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 394728-98-4 HCPLUS
 CN Glycinamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394729-04-5 HCPLUS
 CN Glycinamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B


RN 394729-13-6 HCPLUS
 CN β-Alaninate, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394729-16-9 HCPLUS
 CN Glycinamide, N-[(2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl)-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 394729-18-1 HCPLUS
 CN Glycinamide, 3-methyl-N-[(phenylamino)carbonyl]-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)




RN 394729-19-2 HCPLUS
 CN β-Alanine, N-[(1,1-dimethylethyl)amino]carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-22-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1-(3-butynylamino)oxoacetyl)-4-pentenyl]-6,6-dichloro-3-[(2S)-3,3-dimethyl-1-oxo-2-[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]butyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)




RN 394729-23-8 HCPLUS
 CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-[(1,1-dimethylethyl)sulfonyl]ethyl)amino]oxoacetyl]-4-pentenyl]amino]carbonyl-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-30-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino]carbonyl]amino]cyclohexylacetyl]-6,6-dichloro-N-[1-(oxo-2-propenylamino)acetyl]-4-pentenyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-31-8 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[(2S)-2-[(1-[(1,1-dimethylethyl)amino]carbonyl)amino]-3,3-dimethyl-1-oxobutyl]-N-[1-[(3-(1-methylcyclopentyl)-3-oxopropyl)amino]oxoacetyl]-4-pentenyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-32-9 HCPLUS
 CN β -Alanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl]-4-oxo-1-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-33-0 HCPLUS
 CN β -Alanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl]glucyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-, 1-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-34-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[(2S)-cyclohexyl-[(1,1-dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-[(4-methyl-3-oxopentyl)amino]oxoacetyl]-4-pentenyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-40-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-[(3-butenylamino)oxoacetyl]-4-pentenyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-44-3 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo-2-propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-45-4 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-46-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 6,6-dichloro-3-[(2S)-cyclohexyl-[(1,1-dimethylethyl)amino]carbonyl]amino]acetyl]-N-[1-(oxo(2-propenylamino)acetyl)-4-pentenyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-47-6 HCPLUS
 CN β -Alaninamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-6-heptenoyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-50-1 HCPLUS
 CN Glycynamide, N-[(1,1-dimethylethyl)amino]carbonyl]-3-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxohexanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-51-2 HCPLUS
 CN β -Alanine, N-[(1S,4R)-bicyclo[2.2.1]hept-2-ylamino]carbonyl]-1-methyl-L-valyl-(1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxyl-3-amino-2-oxo-6-heptenoyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-52-3 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-[oxo(2-propenylamino)acetyl]-4-pentenyl)amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394729-58-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(2S)-[(1S,4R)-bicyclo[2.2.1]hept-2-ylamino]carbonyl]amino]cyclohexylacetyl]-N-[1-[(3-butylamino)oxoacetyl]-4-pentenyl]-6,6-dichloro-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394729-65-8 HCPLUS
 CN Carbamic acid, [(1S)-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-[(methylamino)oxoacetyl]butylamino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394729-67-0 HCPLUS

CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl)-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394729-82-9 HCPLUS

CN Carbamic acid, [(1S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394729-83-0 HCPLUS

CN Carbamic acid, [(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394729-87-4 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-[(2S)-cyclohexyl-[(1,1-dimethylethyl)amino]carbonyl]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 394729-89-6 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-38-2 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-cyclohexyl-[(1,1-dimethylethyl)amino]carbonyl]acetyl]-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-39-3 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1-(amino)acetyl)butyl]-6,6-dichloro-3-[(2S)-cyclohexyl-[(1,1-dimethylethyl)amino]carbonyl]aminoacet yl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-40-6 HCPLUS

CN Carbamic acid, [(1S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-41-7 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
N-[3-amino-1-(cyclopropylmethyl)-



2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-42-8 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
N-[3-amino-1-(cyclopropylmethyl)-
2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl-,
(1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-45-1 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-
2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-
3,3-dimethyl-1-oxobutyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394730-46-2 HCPLUS
CN Carbamic acid,
[(1S)-2-[(1S,2S,5R)-2-[(1-(amino)oxoacetyl)butyl]amino]carbonyl]-
6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-
yl)-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-48-4 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide,
N-[3-amino-1-(cyclopropylmethyl)-


2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-2-
,3-dihydro-1H-inden-2-yl]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-49-5 HCPLUS
CN Carbamic acid,
[(1S)-2-[(1S,2S,5R)-2-[(1-(amino)oxoacetyl)butyl]amino]carbonyl]-
6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394730-53-1 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-(amino)oxoacetyl]butyl]-6,6-
dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-
dimethyl-1-oxobutyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394730-54-2 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-(amino)oxoacetyl]butyl]-6,6-
dichloro-3-[(2S)-2-(2,3-dihydro-1H-inden-2-yl)-[(1,1-dimethylethyl)amino]carbonyl]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-55-3 HCPLUS


CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394730-61-1 HCPLUS


CN Carbamic acid, [(1S)-1-[(1S,2S,5R)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 394730-66-6 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)-6,6-dichloro-3-[(2S)-(2,3-dihydro-1H-inden-2-yl){[(1,1-dimethylethyl)amino]carbonyl}amino]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395645-10-0 HCPLUS

CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-62-2 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl{[(1,2,2-trimethylpropyl)amino]carbonyl}amino]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394730-63-3 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl{[(1,1-dimethylethyl)amino]carbonyl}amino]acetyl-, (1S,2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395645-14-4 HCPLUS

CN Carbamic acid, [(1S)-2-[(2S)-2-[(1-aminooxooacetyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395645-88-2 HCPLUS


CN Carbamic acid, [2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395646-26-1 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-37-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl[(cyclohexylamino)carbonyl]amino]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-42-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl[(1,1-dimethylethyl)amino]carbonyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-44-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl[(1,1-dimethylethyl)amino]carbonyl]amino]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-45-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-cyclohexyl[(1,2,2-trimethylpropyl)amino]carbonyl]amino]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-46-8 HCPLUS
 CN Carbamic acid, [(1S)-2-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, tricyclo[3.3.1.13,7]dec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395647-69-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[1-(aminooxocetyl)butyl]-6,6-dichloro-3-[(2S)-cyclohexyl[(1,1-dimethylethyl)amino]carbonyl]amino]acet yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395647-71-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-[(cyclohexylamino)carbonyl]amino] (2,3-dihydro-1H-inden-2-yl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395647-75-3 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-(2,3-dihydro-1H-inden-2-yl)dimethylaminocarbonyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395648-09-6 HCPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2-[(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395648-58-5 HCPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2-[(1-(amino)oxoacetyl)butyl]amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395648-60-9 HCPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2-[(3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 395648-50-7 HCPLUS



CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395648-57-4 HCPLUS



CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(cyclohexylamino)carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)



RN 395648-63-2 HCPLUS


CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[3-amino-1-(cyclopropylmethyl)-2,3-dioxopropyl]-6,6-dichloro-3-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 395650-31-4 HCAPLUS
 CN Glycinamide.
 (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395650-32-5 HCAPLUS
 CN Glycinamide.
 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395650-47-2 HCAPLUS
 CN Glycinamide, 2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 395650-51-8 HCAPLUS
 CN Glycinamide.
 (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-β-amino-α-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 395657-22-4 HCAPLUS
 CN Carbamic acid, [(1S)-1-cyclohexyl-2-[(2S)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl)-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 395650-49-4 HCAPLUS
 CN Glycinamide, (2S)-2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 395659-36-6 HCAPLUS
 CN Carbamic acid, [1-cyclohexyl-2-[(2S)-6,6-dichloro-2-[(1-oxo(2-propenylamino)acetyl)-4-pentenyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-23-8 HCAPLUS
 CN Carbamic acid, [(2-[(2S)-2-[(1-((3-butenylamino)oxoacetyl)-4-pentenyl)amino]carbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,3-dihydro-1H-inden-2-yl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-24-9 HCPLUS
 CN Carbamic acid, [1-[(2S)-2-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-2,2-dimethylpropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-25-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl)-6,6-dichloro-3-[cyclohexyl]amino]carbonyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-29-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, 3-[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino)cyclohexylacetyl]-N-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl)-6,6-dichloro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-32-9 HCPLUS
 CN Carbamic acid, [2-[(2S)-2-[(1-[(3-butenylamino)oxoacetyl]-4-pentenyl)amino]carbonyl]-6,6-dichloro-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-38-5 HCPLUS
 CN β -Alaninamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-54-5 HCPLUS
 CN Carbamic acid, [1-cyclohexyl-2-[(2S)-6,6-dichloro-2-[(1-oxo-2-propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-64-7 HCPLUS
 CN Glycaminide, 2-(2,3-dihydro-1H-inden-2-yl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxohexanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-71-6 HCPLUS
 CN β -Alanine, 2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-heptenoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 395660-72-7 HCAPLUS
 CN β -Alanine, 2-cyclohexyl-N-[(1,1-dimethylethyl)amino]carbonyl]glycyl-
 (2S)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carbonyl-3-amino-2-oxo-6-
 heptenoate, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395660-85-2 HCAPLUS
 CN Carbamic acid,
 (1S)-1-cyclohexyl-2-[(1S,2S,5R)-6,6-dichloro-2-[(1-oxo(2-
 propenylamino)acetyl]butyl]amino]carbonyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-
 oxoethyl]-, 2-methylcyclopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil medline,biosis,embase,hcaplus;s saksena ?/au
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 24.62 187.45
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE -2.19 -2.19

FILE 'MEDLINE' ENTERED AT 10:37:29 ON 09 MAR 2005

FILE 'BIOSIS' ENTERED AT 10:37:29 ON 09 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:37:29 ON 09 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 10:37:29 ON 09 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L5 576 FILE MEDLINE
L6 832 FILE BIOSIS
L7 545 FILE EMBASE
L8 821 FILE HCAPLUS

TOTAL FOR ALL FILES
L9 2774 SAKSENA ?/AU

=> s 19 and (ns3 or serine protease inhibit?)
L10 0 FILE MEDLINE
L11 1 FILE BIOSIS
L12 0 FILE EMBASE
L13 7 FILE HCAPLUS

TOTAL FOR ALL FILES
L14 8 L9 AND (NS3 OR SERINE PROTEASE INHIBIT?)

=> dis his

(FILE 'HOME' ENTERED AT 10:32:26 ON 09 MAR 2005)

FILE 'REGISTRY' ENTERED AT 10:32:38 ON 09 MAR 2005

L1 STR
L2 7 S L1
L3 155 S L1 FUL

L4 3 S L3

FILE 'MEDLINE, BIOSIS, EMBASE, HCAPLUS' ENTERED AT 10:37:29 ON 09 MAR 2005
L5 576 FILE MEDLINE
L6 832 FILE BIOSIS
L7 545 FILE EMBASE
L8 821 FILE HCAPLUS
TOTAL FOR ALL FILES
L9 2774 S SAKSENA ?/AU

```
L10          0 FILE MEDLINE
L11          1 FILE BIOSIS
L12          0 FILE EMBASE
L13          7 FILE HCAPLUS
TOTAL FOR ALL FILES
L14          8 S L9 AND (NS3 OR SERINE PROTEASE INHIBIT?)

=> s l14 not 14
L15          0 FILE MEDLINE
L16          1 FILE BIOSIS
L17          0 FILE EMBASE
L18          4 FILE HCAPLUS

TOTAL FOR ALL FILES
L19          5 L14 NOT L4

=> dup rem l19
PROCESSING COMPLETED FOR L19
L20          5 DUP REM L19 (0 DUPLICATES REMOVED)

=> d 1-5 cbib abs
```


L20 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 2004:431257 Document No.: PREV200400435814. Peptides as NS3-serine protease inhibitors of hepatitis C virus. Saksena, Anil K. (Inventor, Reprint Author); Girijavallabhan, Viyyoor Moopil (Inventor); Lovey, Raymond G. (Inventor); Jao, Edwin (Inventor); Bennett, Frank (Inventor); McCormick, Jinping L. (Inventor); Wang, Haiyan (Inventor); Pike, Russell E. (Inventor); Bogen, Stephane L. (Inventor); Liu, Yi-Tsung (Inventor); Arasappan, Ashok (Inventor); Parekh, Tejal (Inventor); Pinto, Patrick A. (Inventor); Njoroge, F. George (Inventor); Ganguly, Ashit K. (Inventor); Brunck, Terence K. (Inventor); Kemp, Scott Jeffrey (Inventor); Levy, Odile Esther (Inventor); Lim-Wilby, Marguerite (Inventor). Parcipppany, NJ, USA. ASSIGNEE: Schering Corporation; Dendreon Corporation. Patent Info.: US 6800434 October 05, 2004. Official Gazette of the United States Patent and Trademark Office Patents, (Oct 5 2004) Vol. 1287, No. 1. http://www.uspto.gov/web/menu/patdata.html. e-file. ISSN: 0098-1133 (ISSN print). Language: English.

AB The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

L20 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2005 ACS on STN (Continued)
 2004:431257 Document No.: PREV200400435814. Peptides as NS3-serine protease inhibitors of hepatitis C virus. Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerite (Schering Corporation, USA; Corvas International, Inc.). PCT Int. Appl. WO 2003062228 A1 20030731, 86 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US1752 20030121. PRIORITY: US 2002-PV350931 20020123.

L20 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2005 ACS on STN
 2003:591172 Document No. 139:133841 Preparation of proline compounds as NS3-serine protease inhibitors for use in treatment of hepatitis C virus infection. Arasappan, Ashok; Bennett, Frank; Bogen, Stephane L.; Chen, Kevin X.; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond G.; Madison, Vincent S.; Nair, Leatha G.; Njoroge, F. George; Saksena, Anil K.; Sannigrahi, Mousumi; Venkatraman, Srikanth; Girijavallabhan, Viyyoor M. (Schering Corporation, USA). PCT Int. Appl. WO 2003062228 A1 20030731, 86 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US1752 20030121. PRIORITY: US 2002-PV350931 20020123.


GI



AB The invention discloses novel peptides I (Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkylxyloxy, alkylaryloxy, arylxyloxy, heterocycloalkyloxy, cycloalkyloxy, alkylaminol, arylaminol, alkylaminol, arylaminol, heteroalkylaminol, cycloalkylaminol, or heterocycloalkylaminol; R1 is (un)substituted 1-aziridinyl, 1-azetidinyl, pyrrolidinyl, or piperidinyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, arylxylo, alkylthio, arylthio, amino, amido, alkylidene, alkylidene, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with proviso) which have HCV protease inhibitory activity as well as methods for prepp. such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus, peptide II (Boc - tert-butoxycarbonyl) was prepd. and showed Ki < 5 μM for inhibition of HCV serine protease.

L20 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2005 ACS on STN
 2002:90074 Document No. 136:151440 Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus. Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerite (Schering Corporation, USA; Corvas International, Inc.). PCT Int. Appl. WO 2002008256 A2 20020131, 197 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, TZ, RU, SE, SG, SI, SK, SL, TJ, TM; TR, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US22826 20010719. PRIORITY: US 2000-PV220109 20000721.

GI





AB Novel peptides I (Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclylsulfonyl, heterocyclylalkylsulfonyl, arylsulfonyl, heteroarylalkylsulfonyl, alkylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, heterocyclyloxy carbonyl, aryloxycarbonyl, heteroarylcarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl; XI = H, alkyl, alkenyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring containing 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1' = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,

L20 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl
having
HCV protease inhibitory activity are disclosed. Thus, peptide II was
prepd. via peptide coupling in soln. and showed $K_i = 1-100$ nM for
inhibition of HCV protease.

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
2002:90007 Document No. 136:151439 Preparation of novel peptides as
NS3-serine protease inhibitors of
hepatitis C virus. Saksena, Anil K.; Girijavallabhan, Viyyoor
Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett,
Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu,
Yi-Tsung; Chan, Tin-Yau; Zhu, Zhenming; Arasappan, Ashok; Chen, Kevin X.;
Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam,
Bama; Njoroge, P. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp,
Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerite; Tamura, Susan
Y.
(Schering Corporation, USA; Corvus International, Inc.). PCT Int. Appl.
WO 2002008187 A1 20020131, 188 pp. DESIGNATED STATES: W, AE, AG, AL,
AM,
AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM,
DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ,
LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO,
RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY,
DE, DK, ES, FI, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE,
SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US22813
20010719. PRIORITY: US 2000-PV220107 20000721.

GI



II

AB Novel peptides I [G, J, Y = independently H, alkyl, alkyl-aryl,
heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl,
alkoxy, alkyl-alkoxy, aryloxy, heteroaryloxy, heterocycloalkyloxy,
cycloalkyloxy, alkylamino, arylamino, alkyl-arylamino, arylamino,
heteroarylamino, cycloalkylamino, and heterocycloalkylamino; Z = O, N,
CH;
W = null, CO, CS, SO2; R1 = COR5, B(OR)2; R5 = H, OH, OR8, NR9R10, CF3,
C2F5, C3F7, CF2R6, R6, COR7; R7 = H, OH, OR8, CHR9R10, NR9R10; R6, R8-10
* independently H, alkyl, aryl, heteroalkyl, cycloalkyl, arylalkyl, peptide

L20 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
deriv., etc.; R, R2-4 = independently H, alkyl, alkenyl, cycloalkyl,
heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido,
ester, carboxylic acid, carbamate, etc.; and their pharmaceutically salts
which have hepatitis C virus (HCV) protease inhibitory activity were
prepd. via soln. or solid-phase peptide coupling methods. Thus, peptide
II was prepd. using solid-phase methods and showed a K_i value in the
range of 0-100 nM for HCV protease inhibitory activity. This invention also
discloses pharmaceutical compns. comprising such compds. as well as
methods of using them to treat disorders assoccd. with the HCV protease.

L20 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
2001:763001 Document No. 135:318715 Preparation of macrocyclic NS3
-serine protease inhibitors of hepatitis C
virus comprising n-cyclic p2 moieties. Chen, Kevin X.; Arasappan, Ashok;
Venkatraman, Srikanth; Parekh, Tejal N.; Gu, Haining; Njoroge, F. George;
Girijavallabhan, Viyyoor M.; Ganguly, Ashit; Saksena, Anil; Jao,
Edwin; Yao, Nanhua H.; Prongay, Andrew J.; Madison, Vincent S.;
Vibulchan (Schering Corporation, USA). PCT Int. Appl. WO 2001077113 A2
20010118, 402 pp. DESIGNATED STATES: W, AE, AG, AL, AM, AU, AZ, BA,
BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI,
GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU,
LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR,
GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.
(English). CODEN: PIXXD2. APPLICATION: WO 2001-US10869 20010403.
PRIORITY: US 2000-PV194607 20000405.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X and Y = independently (cyclo)alkyl,
heteroalkyl, (aryl)heteroaryl, alkyl(hetero)aryl, substituted ether,
sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide,
carbonyl, etc.; R1 = CHO, acyl, or (un)substituted carboxy, carbamoyl,
boryl, etc.; Z = O, N, or CH, W = null or CO, CS, or SO2; Q = null or CH,
N, P, (CH2)p, (CHR)p, (CRR')p, O, NR, S, or SO2; A = O, CH2, (CHR)p,
(CHRCHR')p, (CRR')p, NR, S, SO2, or a bond; E = CH, N, CR, or a double
bond toward A, L, or G; G = null or (CH2)p, (CHR)p, or (CRR')p; J = null
or CH, CR, O, S, or NR; M = null or O, NR, S, SO2, -(CH2)p, (CHR)p,
(CHRCHR')p, or (CRR')p; p = 0-6; R, R', R2, R3, and R4 = independently H,
(cyclo)alkyl, alkenyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio,
arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone,
CHO, CN, NO2, O, N, S, P, etc.] were prepared as hepatitis C virus (HCV)
protease inhibitors. For example, II (multi-step preparation given) was
cyclized, deesterified, and coupled with III+HCl (preparation given) to
give the macrocyclic hydroxyamide intermediate. Oxidation using
Dea-Martin
reagent followed by flash chromatog. afforded two diastereomers IV in 82%
combined yield. The (S)-isomer inhibited NS3-serine protease
HeLa/Huh7 co-transfected cells with a K_i of 2 μ M. The invention also
discloses pharmaceutical compns. comprising I as well as methods of using
them to treat disorders associated with the HCV protease.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.00	214.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-5.11

STN INTERNATIONAL LOGOFF AT 10:38:32 ON 09 MAR 2005